Glucotrack Faces Nasdaq Delisting Risk Over Price and Equity Non-Compliance

Glucotrack has received a formal notice from Nasdaq indicating that its shares are subject to delisting due to failure to maintain the minimum bid price of $1.00 and the required $2.5 million in stockholders' equity. According to reports, the company intends to request a hearing by May 18, 2026, a move designed to temporarily stay the delisting process pending a regulatory review of its compliance plan.

This development occurs as small-cap biotech firms face intense financing pressures, with SEC filings indicating the company has struggled with accumulated deficits and liquidity constraints. Compared to peers in the glucose monitoring sector, such as Dexcom which trades at significantly higher valuations, Glucotrack's crisis highlights the difficulty of maintaining primary exchange listings when market capitalization falls below Nasdaq's strict thresholds, per market data.

Investors should closely watch the May 18, 2026 deadline for the hearing request, as failure to secure a stay could result in the stock moving to over-the-counter (OTC) markets. Regarding upcoming catalysts, the market awaits Fed Goolsbee's speech on May 12, 2026, which may impact risk appetite for startup sectors, while GCTK shares remain under heavy pressure due to immediate liquidity and regulatory risks.